Article by New Cannabis Ventures
British Sugar, the leading UK beet sugar producer, announces today that its horticultural business is to grow a key ingredient for the pharmaceutical sector.
This ingredient will be used in a new prescription medicine being developed to treat rare but serious forms of epilepsy in children. The medicine, known as Epidiolex, has recently completed trials at the Great Ormond Street Hospital for Children in London as well as other hospitals in the UK, Europe and the US. This contract with GW Pharmaceuticals is a further step in making this medicine more widely available.
The active ingredient in Epidiolex is known as Cannabidiol (CBD), and it is sourced from a non‐psychoactive variety of the cannabis plant family, specifically bred for medical purposes. We will start to grow these plants from 2017.
The crop will replace production of tomatoes to be phased out from November and we remain committed to meeting our existing supply commitments for tomatoes.